[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"male-urogenital-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:male-urogenital-diseases":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,75,103,130,166,196,223],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100402904","phase-2-early-oxybutinin-treatment-for-boys-with-posterior-urethral-valves-100402904",false,"NCT04526353","Early Oxybutinin Treatment for Boys With Posterior Urethral Valves","Prospective Randomized Clinical Trial of Early Oxybutinin Treatment for Boys With Posterior Urethral Valves","PRETIPUV","Inclusion Criteria:\n\n* Boys\n* Aged 3 to 6 months\n* Diagnosed with posterior urethral valves, and having undergone valve resection within the first 3 months of life\n* Children who have had their valve resection at least 3 months before inclusion\n* Having undergone urodynamic studies between 10 weeks and 6 months of age andshowing abnormal urodynamics, notably: high voiding pressure (\\>60cm H2O)\u002F small capacity bladder (\\\u003C70% expected bladder volume)and for those without pop-off mechanisms, poor compliance (\\\u003C10ml\u002FcmH2O)\u002F\n* Holders of parental authority affiliated to French national health insurance\n* With informed consent signed by holders of parental authority\n\nExclusion Criteria:\n\n* Boys with posterior urethral valves and normal urodynamics or no urodynamic assessment\n* Boys in whom urodynamic assessment is not possible for medical or anatomical reasons\n* Boys requiring dialysis before the age of 3 months\n* Contra-indication to oxybutynin such as hypersensitivity to oxybutynin or any of the excipients, digestive obstruction, occlusive or sub-occlusive syndrome, megacolon, digestive stasis, intestinal atony, paralytic ileus, ulcerative colitis, Hemorrhagic rectocolitis, Crohn's disease, Inflammatory bowel disease, Inflammatory organic colopathy, myasthenia, congenital glaucoma","MALE","3 Months","6 Months",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Boys with posterior urethral valves have bladder dysfunction of varying severity. Early treatment of these children with anticholinergics is recommended by some teams, although there have never been any clear studies on the subject. To our knowledge, no comparative study of the evolution of valve bladders with or without treatment has been carried out to date.\n\nAnticholinergic treatment, although it may be beneficial in patients with abnormal bladder function, such as the neurologic bladders ( in Spina Bifida) for example, may have side effects and may not be of benefit for this valve population. The evolution of the valves could be spontaneously favorable.\n\nThis study would be the first randomized clinical trial of early therapeutic drug intervention in the posterior urethral valve population.",[28],"Male Urogenital Diseases",[30,31,32],"posterior urethral valves","urodynamic","anticholinergic","RECRUITING","2026-06-08",{"date":36,"type":37},"2026-06-10","ACTUAL",{"date":39,"type":37},"2020-09-10",{"date":41,"type":22},"2028-09-10",{"name":43,"class":44},"University Hospital, Bordeaux","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100305626","phase-1-safety-and-feasibility-study-of-autologous-engineered-urethral-constructs-for-the-treatment-of-strictures-100305626","NCT03258658","Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures","A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral","Inclusion Criteria:\n\n* Stricture of the urethra meeting the following criteria:\n\n  a) History of at least one 15-60 mm in length, as determined by urethrography. c) Contains at least 1 strictured segment through which a 16 Fr flexible cystoscope cannot be atraumatically passed.\n* Patients must be available for all follow-up visits.\n* Ability to speak English.\n\nExclusion Criteria:\n\n* Strictures of the meatus or prostatic urethra; any urethral stricture associated with or suspected to be urethral carcinoma, or strictures due to pelvic distraction injuries. Strictures \\\u003C10 mm or \\>60 mm, as determined by urethrography, and criteria for bulbar urethral strictures excluding those with strictures \\\u003C20 mm and \\>60 mm, as described by urethrography.\n* Presence of untreated urinary tract infection.\n* Presence or prior history of lichen sclerosis et atrophicus (previously termed 'balanitis xerotica obliterans').\n* Uncontrolled bleeding disorder or patients with a platelet count less than 50,000, hemophilia or patients routinely receiving blood products for bleeding disorders.\n* Any urological condition that would be likely to require additional urethral instrumentation during the period of investigation, including, but not limited to benign prostatic hyperplasia requiring treatment, use of alpha blockers, active prostate cancer, an unevaluated elevated prostate surface antigen (PSA), bladder cancer, or any recurrent urinary stone formation. Patients with evidence or diagnosis of any coagulation disorder (including concomitant anti-coagulation therapy at enrollment).\n* Serum creatinine \\> 2.0 mg\u002Fdl or evidence of progressive renal disease.\n* Patients with abnormal urologic conditions, including vesicoureteral reflux, bladder stones, bladder tumors and renal impairment.\n* Subjects with an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \\>3 times the upper limit of normal.\n* Subjects with an albumin value \\\u003C3.0 g\u002FdL.\n* Subjects with uncontrolled diabetes, unstable cardiac and\u002For pulmonary disorders.\n* Subjects with active tuberculosis (TB) requiring treatment in the past 3 years. Subjects with a current positive (≥5 mm induration for high-risk subjects; otherwise ≥10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.\n* Subjects known to be colonized with either methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), or gentamicin-resistant organisms.\n* Immunocompromised subjects or subjects receiving immunosuppressive agents (inhaled corticosteroids and chronic low-dose corticosteroids \\[≤0.25 mg\u002Fkg prednisone or equivalent per day\\] are permitted).\n* Any history of alcohol and\u002For drug abuse.\n* Current smoker.\n* Documented history of, or positive result of HIV, Hepatitis B or C, or any infectious disease. External signs, sequelae, or positive serology of sexually transmitted disease (including HPV).\n* Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study.\n* Concurrent participation in any other clinical investigation during the period of this investigation. Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study.\n* Any current illness that might confound the results of this investigation, including but not limited to bladder atonia, neuropathic\u002Fneurogenic bladder, bladder outlet obstruction (other than urethral stricture), sphincteric dysfunction, or spinal cord injury.\n* Any circumstance in which the investigator deems participation in the study is not in the subject's best interest.\n* Inability to participate in all necessary study activities due to physical or mental limitations.\n* Inability or unwillingness to return for all required follow-up visits.\n* inability or unwillingness to sign informed consent.\n* Patients requiring concomitant use of or treatment with immunosuppressive agents.\n* Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease).","21 Years","75 Years",{"count":56,"type":22},10,[58],"PHASE1","This is a Phase I clinical study to determine the safety and efficacy of using autologous, engineered urethral constructs for the treatment of urethral strictures in adult males.\n\nThe proposed study design is a prospective non-randomized and uncontrolled single-center investigation. Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to seed tubular PGA scaffolds to create autologous urethral constructs for the repair of urethral strictures.",[61,28,62,63],"Urologic Diseases","Urethral Stricture","Urethral Injury",[62],"2026-06-03",{"date":67,"type":37},"2026-06-04",{"date":69,"type":22},"2026-08",{"date":71,"type":22},"2029-12",{"name":73,"class":44},"Wake Forest University Health Sciences",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":45},"100321313","phase-1-bioengineered-penile-tissue-constructs-for-irreversibly-damaged-penile-corpora-100321313","NCT03463239","Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora","Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora","Inclusion Criteria:\n\n1. Males aged 18-60 years.\n2. Acquired structural abnormalities of the corpora cavernosum secondary to trauma, infection, inflammation, or fibromatosis. These abnormalities will be diagnosed by clinical examination, and\u002For ultrasound, and\u002For computerized tomography.\n3. Stable abnormalities - at least 6 months with no pain or changes in deformity.\n4. At least one failed attempt at management by conventional approaches at least 6 months prior to enrollment\n5. Deformities less than 5 cm in length.\n6. Written informed consent obtained prior to participation in the study.\n7. Patients must be available for all follow up visits.\n8. Ability to speak English.\n\nExclusion Criteria:\n\n1. Presence of untreated or incompletely treated urinary tract infection at the time of biopsy.\n2. Uncontrolled bleeding disorder or patients with a platelet count less than 50,000, hemophilia or patients routinely receiving blood products for bleeding disorders.\n3. Serum creatinine \\> 2.0 mg\u002Fdl or evidence of progressive renal disease.\n4. ALT or AST value \\>1.5 times the upper limit of normal.\n5. Albumin \\\u003C 3.0 g\u002FdL.\n6. Serum direct bilirubin \\>0.3 mg\u002FdL OR total bilirubin \\> 1.4 mg\u002FdL\n7. BM I\\>40 kg\u002Fm2\n8. Uncontrolled diabetes with HbA1C\\>9%. (Subjects with controlled diabetes must be under care of diabetologist with treatment goals consistent with ADA criteria).\n9. Unstable cardiac disorders within the past 6 months including angina, abnormal ECG, history of cardiac arrest, surgery and\u002For other interventional procedure.\n10. Unstable pulmonary disorders within the past 6 months including dyspnea on exertion, chronic productive cough, pneumonia, hemoptysis, asthma requiring nebulized therapy.\n11. Active tuberculosis (TB) requiring treatment in the past 3 years. Subjects with a current positive (≥5 mm induration for high-risk subjects; otherwise ≥10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.\n12. Known to be colonization with either methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), or gentamicin-resistant organisms.\n13. Immunocompromised subjects or subjects receiving immunosuppressive agents.\n14. Any history of alcohol and\u002For drug abuse.\n15. Documented history of, or positive result of HIV, Hepatitis B or C, or any infectious disease. External signs, sequelae, or positive serology of sexually transmitted disease (including HPV). Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study.\n16. Concurrent participation in any other clinical investigation during the period of this investigation. Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study.\n17. Any circumstance in which the investigator deems participation in the study is not in the subject's best interest.\n18. Inability to participate in all necessary study activities due to physical or mental limitations.\n19. Inability or unwillingness to return for all required follow-up visits, for instance life expectancy \\\u003C 1 year, or subject who knows they will be moving out of the country and unable to return for follow-up visits.\n20. Inability or unwillingness to sign informed consent.\n21. Patients requiring concomitant use of or treatment with immunosuppressive agents\n22. Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease).","18 Years","60 Years",{"count":56,"type":22},[58],"The primary objective of this clinical trial is to evaluate the safety of autologous engineered corpora cavernosa + albuginea constructs for treatment of complex penile deformities. Autologous endothelial and smooth muscle cells obtained from enrolled subjects' corpora cavernosa biopsy sample, will be culture expanded in vitro and used to seed decellularized corpora cavernosa + albuginea obtained from cadaveric-donors to create autologous bioengineered corpora cavernosa\u002Falbuginea constructs for repair of damaged penile tissues.",[61,28,88,89,90,91],"Penile Diseases","Corpus Callosum Malformation","Corpora Cavernosa; Inflammation","Trauma Injury",[93],"Autologous tissue engineered corpora","NOT_YET_RECRUITING","2026-03-26",{"date":97,"type":37},"2026-03-27",{"date":99,"type":22},"2026-10",{"date":101,"type":22},"2030-12",{"name":73,"class":44},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":74},"100543287","phase-2-carboplatinpaclitaxel--pembrolizumab-for-locoregionally-advanced-penile-cancer-100543287","NCT06353906","Carboplatin\u002FPaclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer","A Phase 2 Clinical Study to Assess Efficacy of Induction Carboplatin\u002FPaclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer: PRIAM","PRIAM","Inclusion Criteria:\n\n1. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n2. Histologically confirmed diagnosis of squamous cell carcinoma of the penis.\n3. Patients have one of the following disease stages:\n\n   * cTxN2-3 or\n   * cTxN1 in case of central nodal necrosis and\u002For an irregular nodal border, or node \\>3cm, or\n   * Inguinal or pelvic lymph node recurrence that is potentially resectable. Any of the disease stages above, in combination with oligometastatic disease with a maximum of 2 distant metastases is allowed, as long as these metastases can be treated by resection or radiotherapy. This should be established in the multidisciplinary tumor board before enrolment.\n4. Archival tumor tissue sample or newly obtained \\[core, incisional or excisional\\] biopsy of a tumor lesion not previously irradiated has been provided. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.\n5. A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period.\n6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 14 days prior to the first dose of study intervention.\n7. Have adequate organ function defined as: absolute neutrophil count (ANC) ≥1.5 10e9 \u002FL, platelets ≥100 10e9\u002FL; hemoglobin ≥9.0 g\u002FdL or ≥5.6 mmol\u002FL; creatinine ≤1.5 × ULN OR GFR\\>30 ml\u002Fmin as per Cockcroft-Gault formula in patients with creatinine levels \\> 1.5x institutional ULN; total bilirubin 1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 × ULN; AST (SGOT) and ALT (SGPT) ≤2.5 × ULN; International normalized ratio (INR), prothrombin time (PT) OR activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants. Specimens must be collected within 14 days prior to the start of study intervention.\n\nExclusion Criteria:\n\n1. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n2. Has received prior systemic anti-cancer therapy including investigational agents, or an investigational device, within 4 weeks prior to registration.\n3. Has received prior radiotherapy within 4 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids.\n4. Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n5. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n6. Known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Exceptions: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded. Patients with low-risk prostate cancer (defined as Stage T1\u002FT2a, Gleason score ≤ 6, and PSA ≤ 10 ng\u002FmL) who are treatment-naive and undergoing active surveillance are eligible.\n7. Has known active or treated CNS metastases and\u002For carcinomatous meningitis.\n8. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n9. Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid). Patients with vitiligo, psoriasis or other mild skin disease can still be included.\n10. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n11. Has an active infection requiring systemic therapy.\n12. Has a known history of Human Immunodeficiency Virus (HIV) infection.\n13. Concurrent active Hepatitis B (defined as HBsAg positive and\u002For detectable HBV DNA) and\u002For Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection. Hepatitis B and C screening tests are not required unless a patient has a known history of HBV or HCV infection. Participants must have completed curative anti-viral therapy at least 6 months prior to randomization.\n14. Has not adequately recovered from major surgery or has ongoing surgical complications.\n15. Major pelvic surgical procedure within 4 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for the disease under study.\n16. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n17. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n18. Is expecting to father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n19. Has had an allogenic tissue\u002Fsolid organ transplant",{"count":112,"type":22},27,[25],"This is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis",[116,117,28,118,119,120],"Urologic Neoplasms","Urogenital Neoplasms","Penile Cancer","Penile Squamous Cell Carcinoma","Locally Advanced Penile Carcinoma","2025-12-05",{"date":123,"type":37},"2025-12-08",{"date":125,"type":37},"2024-08-13",{"date":127,"type":22},"2028-01-14",{"name":129,"class":44},"The Netherlands Cancer Institute",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":137,"minAge":82,"maxAge":138,"enrollmentInfo":139,"targetDuration":141,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":154,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":45},"100568077","vorolanib-in-the-second-line-treatment-of-patients-with-unresectable-or-metastatic-renal-cell-carcinoma-100568077","NCT06676527","Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n* Subjects have fully understood and voluntarily signed the informed consent form (ICF);\n* 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;\n* Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;\n* According to RECIST (version 1.1), there are targets that are considered to be observable;\n* The main organs function well.\n\nExclusion Criteria:\n\n* A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);\n* Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;\n* Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;\n* A history of severe drug allergy, including but not limited to antibody drugs;\n* Patients with contraindications for immunotherapy restart;\n* A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;\n* Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion\u002Fexclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;\n* Have central nervous system metastases and\u002For cancerous meningitis;\n* Known history of clinically significant liver disease, including those infected with viral hepatitis activity;\n* Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);\n* Patients with any severe and\u002For uncontrolled disease;\n* Renal failure requires hemodialysis or peritoneal dialysis;\n* Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;\n* History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;\n* Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;\n* Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.","ALL","80 Years",{"count":140,"type":22},39,"12 Weeks","OBSERVATIONAL","This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.",[145,146,116,117,147,28,148,149,61,150,151,152,153],"Neoplasms","Kidney Neoplasms","Female Urogenital Diseases","Urogenital Diseases","Kidney Diseases","Carcinoma","Renal Cell Cancer","Carcinoma, Renal Cell","Antineoplastic Agents",[155,156,157],"observational study","clear cell Renal Cell Carcinoma","TKIs","2025-12-04",{"date":121,"type":37},{"date":161,"type":37},"2024-09-01",{"date":163,"type":22},"2026-09-01",{"name":165,"class":44},"Jinling Hospital, China",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":137,"minAge":82,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":184,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100534368","phase-2-stage-ii-iiia-urothelial-cancer-randomizing-pre-operative-nivolumab-with-or-without-relatlimab-100534368","NCT06237920","Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab","A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab","TURANDORELA","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Age ≥ 18 years\n* Resectable muscle-invasive UC of the bladder, defined as cT2-4aN0M0 OR cT1-4aN1M0. In cT1N1 patients, lymph node positivity would need to be cytologically or histologically confirmed.\n* Surgical resection (cystectomy) is the advised locoregional treatment and is accepted by the subject after consultation with the urologist.\n* Patients are either cisplatin ineligible or elect to not undergo cisplatin based neoadjuvant chemotherapy after a balanced discussion of risks and benefits with the treating physician. Cisplatin eligibility is determined based on the Galsky criteria\n* World Health Organization (WHO) performance Status 0 or 1.\n* Urothelial cancer is the dominant histology (\\>50%). Any component of small cell or adenocarcinoma is not allowed.\n* Formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks from diagnostic TUR available.\n* Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109\u002FL, Platelets ≥100 x109\u002FL, Hemoglobin ≥5.5 mmol\u002FL, GFR\\>30 ml\u002Fmin, AST ≤ 1.5 x ULN, ALT ≤1.5 x ULN, Bilirubin ≤1.5 X ULN\n* Negative pregnancy test (βHCG in blood or urine) within 2 weeks of Day 1 Cycle 1 for female patients of childbearing potential.\n* Highly effective contraception for female subjects if the risk of conception exists. Female patients of childbearing potential must comply with contraception methods as requested by the study protocol (→ 8.2.1 Pregnancy, contraception and breastfeeding)\n\nExclusion Criteria:\n\n* Subjects with active autoimmune disease in the past 2 years. Patients with diabetes mellitus, properly controlled hypothyroidism or hyperthyroidism, vitiligo, psoriasis or other mild skin disease can still be included.\n* Documented history of severe autoimmune disease (e.g. inflammatory bowel disease, myasthenia gravis).\n* Previous intravenous systemic therapy or radiotherapy for UC.\n* Upper urinary tract disease, unless all disease is planned to be resected in the same surgery as for UBC. This includes non-muscle-invasive disease.\n* Prior CTLA-4, LAG3 or PD-1\u002FPD-L1-targeting immunotherapy.\n* Known active Human Immunodeficiency Virus infection, or tuberculosis, or other active infection:\n* HIV-positive patients are eligible if the following applies:\n* No AIDS defining opportunistic infection within the last year and a current CD4 count \\>350 cells\u002FuL.\n* Received antiretroviral therapy (ART) for at least 4 weeks prior to treatment and continued while enrolled on study\n* CD4 counts and viral load are monitored per standard of care by a local health care provider\n* In patients with a known history of hepatitis B or hepatitis C infection, Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA) should be negative\n* Underlying medical conditions that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of adverse events. Examples may include severe pulmonary disease with extensive radiological abnormalities or intestinal disease causing severe diarrhea, not covered by other eligibility criteria, that may obscure colitis.\n* Medical condition requiring the use of immunosuppressive medications, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\u002Fday of prednisone, or an equivalent corticosteroid. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) will be allowed.\n* Use of other investigational drugs before study drug administration.\n* Malignancy, other than urothelial cancer, in the previous 2 years, with a high chance of recurrence (estimated \\>10%). Patients with low-risk prostate cancer (defined as Stage T1\u002FT2a, Gleason score ≤ 6, and PSA ≤ 10 ng\u002FmL) who are treatment-naive and undergoing active surveillance are eligible.\n* Pregnant and lactating female patients.\n* Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.\n* Severe infections within 2 weeks prior to enrolment in the study including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to enrolment, unstable arrhythmias and unstable angina.",{"count":175,"type":22},90,[25],"This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment option for patients responding to treatment",[116,117,179,145,147,180,148,181,28,182,183],"Neoplasms by Site","Female Urogenital Diseases and Pregnancy Complications","Urinary Bladder Diseases","Urinary Bladder Neoplasm","Antineoplastics Toxicity",[185,186],"Nivolumab","Relatlimab","2025-09-01",{"date":189,"type":37},"2025-09-03",{"date":191,"type":37},"2024-02-19",{"date":193,"type":22},"2028-08-01",{"name":129,"class":44},9,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},"100566803","the-radium-select-study-100566803","NCT06659926","The Radium-select Study","68Ga-PSMA-PET\u002FCT and Genomic Alterations for Future Selection of Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) for Radium-223 Treatment.","Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the prostate.\n* Progressive disease after previous treatment defined as a rise in serum (Prostate Specific Antigen) PSA (PCWG3 criteria(22), see appendix 1) and\u002For progression on conventional imaging (PCWG3).\n* A positive bone scan (osteoblastic bone metastases), with at least two metastases.\n* Hemoglobin concentration \\>10 g\u002Fdl (6.2 mmol\u002Fl) and thrombocytes \\>100 109\u002FI at baseline.\n* Each patient will need to (continue to) receive adequate bone protective agents (e.g. bisphosphonates) and androgen deprivation therapy (ADT) according to current clinical guidelines.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance score \\>2\n* Life expectancy \\\u003C 6 months.\n* Detected extra-skeletal metastases or lymph node metastases (\\>3 cm short axis) as identified by conventional imaging (ceCT thorax\u002Fabdomen)",{"count":204,"type":22},60,[206],"NA","Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis. Patients are eligible for this treatment when they have mCRPC and bone metastases; limited extraskeletal lesions (local prostate, lymph nodes \\\u003C3 cm) on conventional contrast enhanced CT (ceCT) were allowed in the registration trial(1). Previous research revealed that extraskeletal disease on ceCT and bone scans correlates with a poor response. Meanwhile, 68Ga-PSMA-PET\u002FCT emerged as more sensitive imaging strategy that increases the detection of extraskeletal prostate cancer metastases. It is unclear whether these extraskeletal lesions harbour any predictive value in the treatment of mCRPC patients with Radium-223.",[209,28],"mCRPC",[209,211,212,213],"68Ga-PSMA-PET\u002FCT","Radium-223","Bone only-disease","2025-07-04",{"date":216,"type":37},"2025-07-08",{"date":218,"type":37},"2025-02-24",{"date":220,"type":22},"2029-07-01",{"name":129,"class":44},5,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":234,"conditions":235,"keywords":243,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":45},"100570413","phase-4-18f-fluciclovine-petct-impact-on-predicting-clinical-outcome-of-177lu-psma-617-therapy-in-patients-with-prostate-cancer-100570413","NCT06706921","18F-Fluciclovine PET\u002FCT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer","Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET\u002FCT Predicting Clinical Outcome","Inclusion Criteria:\n\n* Patients with mCRPC scheduled to undergo LuPSMA RLT.\n* Willingness to undergo multiple serial PET\u002FCT scans pre- and post-LuPSMA RLT.\n* Ability of providing written informed consent.\n\nExclusion Criteria:\n\n* Less than 18 years-old at the time of radiopharmaceutical administration.\n* Medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study procedures or compliance.\n* Contraindications to LuPSMA RLT.",{"count":231,"type":22},15,[233],"PHASE4","This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography\u002Fcomputed tomography 18F-FDG PET\u002FCT and a 18F-DCFPyL PET\u002FCT (18F-DCFPyL (2-(3-{1-carboxy-5-\\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\\]-pentyl}-ureido)-pentanedioic acid)positron emission tomography\u002Fcomputed tomography , as per standard of care in our institution. All patients further undergo eventual follow-up prostate-specific membrane antigen positron emission tomography (PSMA PET) after the 2nd, 4th, and 6th LuPSMA RLT cycle. In this prospective study, an18F-Fluciclovine positron emission tomography\u002Fcomputed tomography ( Axumin PET\u002FCT )will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles. Axumin PET\u002FCT will be acquired within 7 days from the PSMA PET.\n\nThis study is open to Veterans only.",[236,237,238,28,239,240,241,145,179,117,242],"Prostatic Neoplasms","Prostatic Neoplasms, Castration-Resistant","Metastatic Prostate Cancer","Prostatic Diseases","Urogenital Diseases, Male","Genital Diseases, Male","Genital Neoplasms, Male",[244,245,246,247,248],"Prostate cancer","PET\u002FCT","Radioligand Therapy","Metastatic Castration-Resistant Prostate Cancer","PSMA PET","2024-11-26",{"date":251,"type":37},"2024-11-27",{"date":253,"type":22},"2024-12-15",{"date":255,"type":22},"2027-11-01",{"name":257,"class":258},"VA Greater Los Angeles Healthcare System","FED"]